These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
276 related items for PubMed ID: 19692558
1. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA. J Clin Microbiol; 2009 Oct; 47(10):3271-5. PubMed ID: 19692558 [Abstract] [Full Text] [Related]
2. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. J Clin Microbiol; 2008 Aug; 46(8):2568-72. PubMed ID: 18562581 [Abstract] [Full Text] [Related]
3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586 [Abstract] [Full Text] [Related]
4. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species. Wang HC, Hsieh MI, Choi PC, Wu CJ. J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391 [Abstract] [Full Text] [Related]
6. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses. Öz Y, Özdemir HG, Gökbolat E, Kiraz N, Ilkit M, Seyedmousavi S. Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621 [Abstract] [Full Text] [Related]
10. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726 [Abstract] [Full Text] [Related]
12. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Demchok JP, Meletiadis J, Roilides E, Walsh TJ. Mycoses; 2010 May; 53(3):239-45. PubMed ID: 19389068 [Abstract] [Full Text] [Related]
13. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559 [Abstract] [Full Text] [Related]
14. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645 [Abstract] [Full Text] [Related]
15. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Kaya AD, Kiraz N. Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704 [Abstract] [Full Text] [Related]
16. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases]. Gürcan S, Tikveşli M, Eryildiz C, Evci C, Ener B. Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962 [Abstract] [Full Text] [Related]
17. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013 [Abstract] [Full Text] [Related]
18. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, Castro C, Chen YC, Chen Y, Chryssanthou E, Dannaoui E, Garcia-Effron G, Gonzalez GM, Govender NP, Guinea J, Kidd S, Lackner M, Lass-Flörl C, Linares-Sicilia MJ, López-Soria L, Magobo R, Pelaez T, Quindós G, Rodriguez-Iglesia MA, Ruiz MA, Sánchez-Reus F, Sanguinetti M, Shields R, Szweda P, Tortorano A, Wengenack NL, Bramati S, Cavanna C, DeLuca C, Gelmi M, Grancini A, Lombardi G, Meletiadis J, Negri CE, Passera M, Peman J, Prigitano A, Sala E, Tejada M. Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038 [Abstract] [Full Text] [Related]
19. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469 [Abstract] [Full Text] [Related]
20. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B. Escribano P, Peláez T, Recio S, Bouza E, Guinea J. Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886 [Abstract] [Full Text] [Related] Page: [Next] [New Search]